Flumazenil mechanism/duration: which statement is correct?

Flumazenil mechanism/duration: which statement is correct?

• A. Increases CNS sympathetic activity
• B. Competitive antagonist of GABA-A receptors with short DOA
• C. Non-competitive agonist at GABA receptors
• D. Acts as a benzodiazepine agonist

Answer: (B)

Flumazenil’s main concept is that it reverses benzodiazepine effects by blocking the benzodiazepine binding site on the GABA-A receptor as a competitive antagonist, and it has a short duration of action. Because it competes for the same site, it prevents benzodiazepines from enhancing the GABA-A receptor’s chloride channel opening, effectively reversing sedation without activating the receptor itself. This explains why it can fully reverse benzo-induced CNS depression but does not act as a benzodiazepine itself. Its short duration stems from rapid hepatic metabolism and redistribution, so the reversal effect can wear off while the original benzodiazepine is still present, especially with long-acting agents. This is why patients must be monitored and redosing or a continuous infusion may be needed in some cases. Flumazenil is not a non-competitive agonist, nor is it an agonist at the GABA-A receptor, and it does not increase CNS sympathetic activity.

Flumazenil’s main concept is that it reverses benzodiazepine effects by blocking the benzodiazepine binding site on the GABA-A receptor as a competitive antagonist, and it has a short duration of action. Because it competes for the same site, it prevents benzodiazepines from enhancing the GABA-A receptor’s chloride channel opening, effectively reversing sedation without activating the receptor itself. This explains why it can fully reverse benzo-induced CNS depression but does not act as a benzodiazepine itself.

Its short duration stems from rapid hepatic metabolism and redistribution, so the reversal effect can wear off while the original benzodiazepine is still present, especially with long-acting agents. This is why patients must be monitored and redosing or a continuous infusion may be needed in some cases.

Flumazenil is not a non-competitive agonist, nor is it an agonist at the GABA-A receptor, and it does not increase CNS sympathetic activity.